CellProthera

Refractory angina (RFA) is chronic chest pain due to furring up of the blood supply to the heart that causes unbearable symptoms and poor quality of life despite current medical treatment, angioplasty, or bypass surgery. New cases are estimated at 75 000 in the US, 30 000- 50 000 in Europe and just under 20 000 in the UK. These patients pose significant healthcare costs as presentations are treated as suspected heart attacks with overnight admissions and frequent hospitalisations. Despite the availability of different treatments for coronary artery disease, RFA patients have limited treatment options as their disease cannot be treated with conventional treatment methods. When a patient with an AMI is admitted to a cardiology emergency unit, he or she is managed by the medical team. If the patient meets the main initial criteria for inclusion in the clinical trial (LVEF< 50%), the investigating doctor will determine whether the patient is suitable to participate in the study by checking, among other things, the patient’s medical history, current state of health, etc. If the patient agrees to participate, he/she signs the consent form and participates in the randomization to be enrolled: